CS0159

Phase 3Small molecule

CCascade Pharmaceuticals, Inc

CS0159 is one of 99 small molecule programs targeting Obesity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

Primary Biliary CholangitisRecruiting

Sclerosing CholangitisActive, not recruiting

ObesityPreclinical

Active, not recruiting

Primary Biliary CholangitisPhase 3

Recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

CS0159

CCascade Pharmaceuticals, Inc

Phase 3

1 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Amidate

Cetrotide

2 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Interaction

NCT07429331

Q1 2028

Phase 3Recruiting

Primary Biliary Cholangitis

NCT07282353

Clinical

Trials by Indication[1]

Tics2 trials

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

Completed·CCascade Pharmaceuticals, Inc·Phase 1·NCT05624294·36 enrolled

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159

Completed·CCascade Pharmaceuticals, Inc·Phase 1·NCT05082779·79 enrolled

Primary Biliary Cholangitis2 trials

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Active, not recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT05896124·75 enrolled

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients With Primary Biliary Cholangitis (PBC) With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Recruiting·CCascade Pharmaceuticals, Inc·Phase 3·NCT07282353·135 enrolled

Injury1 trial

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

Completed·CCascade Pharmaceuticals, Inc·Phase 1·NCT06888115·24 enrolled

Obesity1 trial

Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM

Completed·SShanghai Jiao Tong University School of Medicine·N/A·NCT06492330·62 enrolled

Sclerosing Cholangitis1 trial

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Active, not recruiting·CCascade Pharmaceuticals, Inc·Phase 2·NCT05896137·50 enrolled

3 more indications

Interaction1 trial

Drug Interaction and Food Effect Study of CS0159

Not yet recruiting·CCascade Pharmaceuticals, Inc·Phase 1·NCT07429331·32 enrolled

Efficacy1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Completed·CCascade Pharmaceuticals, Inc·Phase 2·NCT05591079·99 enrolled

Unspecified1 trial

Study of [14C]CS0159 in China Healthy Subjects

Completed·CCascade Pharmaceuticals, Inc·Phase 1·NCT06098027·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for CS0159. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CS0159 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CS0159. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cascade Pharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCascade Pharmaceuticals, Inc

CS0159

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Tics2 trials

Primary Biliary Cholangitis2 trials

Injury1 trial

Obesity1 trial

Sclerosing Cholangitis1 trial

Interaction1 trial

Efficacy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News